Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lopinavir

FDA-approved product (capsule, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lopinavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Lopinavir reaches ≥40% AI-predicted activity against M. tuberculosis and MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lopinavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lopinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

    NCT00028301 · start 2001-02

    Registered record
    Registry ID
    NCT00028301
    Conditions
    HIV Infections
    Interventions
    Atazanavir; Lopinavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2003-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir; Lopinavir/Ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Special Investigation of Kaletra in Pregnant Women

    NCT01076985 · start 2000-12

    Registered record
    Registry ID
    NCT01076985
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Lopinavir/ritonavir (Kaletra)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-12
    Completion
    2010-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionLopinavir/ritonavir (Kaletra)
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

    NCT00038636 · start 2000-09

    Registered record
    Registry ID
    NCT00038636
    Conditions
    HIV Infections
    Interventions
    Lopinavir/ritonavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-09
    Completion
    Not recorded
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLopinavir/ritonavir; Ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

    NCT00028366

    Registered record
    Registry ID
    NCT00028366
    Conditions
    HIV Infections
    Interventions
    Fosamprenavir; Lopinavir/Ritonavir; Ritonavir; Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionFosamprenavir; Lopinavir/Ritonavir; Ritonavir; Tenofovir disoproxil fumarate
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

    NCT00036452

    Registered record
    Registry ID
    NCT00036452
    Conditions
    HIV Infections
    Interventions
    lopinavir/ritonavir; emtricitabine; stavudine; tenofovir DF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-01
    Enrolment
    402

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionlopinavir/ritonavir; emtricitabine; stavudine; tenofovir DF
    PhasePhase 2
    Registry statusCompleted